2025 China Cell and Gene Therapy Summit Opens in Beijing, Charting a New Global Industry Landscape

Rooted in Regulation, Harnessing Wisdom, Connecting Globally, Co-creating the Future. China’s Cell and Gene Therapy Sector Welcomes Its Premier Annual Summit.

2025Year9Month12Sun to13On the day, China Cell and Gene Therapy Conference (CSGCT) was grandly held at the Zhongguancun Exhibition and Trading Center in Haidian District, Beijing. Under the guidance of the People's Government of Haidian District, Beijing, this conference was organized by the Administrative Committee of Zhongguancun Science City andCSGCTCo-hosted by the China Cell and Gene Therapy Alliance,HIEAOrganized by the Medical Innovation Ecosystem Alliance and VCBeat.

Guided by the core philosophy of “Regulatory Foundation, Collective Wisdom, Global Connectivity, and Shared Future,” the conference...themed “China’s Strength,” established1VBInsight Forum,15Sub-forums and2On-site project roadshow, attracting including10Remaining International SeatsCGTLeading scientists, clinicians, entrepreneurs, investors, and other prominent figures2000Guests attended the conference to jointly discuss the development strategy for cell and gene therapy.

Main Forum Venue

At the main forum of the aforementioned conference, leaders from the Beijing Municipal Science and Technology Commission, the Zhongguancun Administrative Committee, the People’s Government of Haidian District, Beijing, and the Zhongguancun Science City Administrative Committee also provided a detailed overview of the current development status of the pharmaceutical and health industries in Beijing and Haidian District.

"Over the past three years, Beijing has ranked first in China for the number of medical device products approved for market launch."2024The annual scale of the pharmaceutical and health industry reached1.06trillion yuan, a year-on-year increase of8.7%“, becoming the first city in China whose pharmaceutical and healthcare industry output value exceeded one trillion yuan.” Tang Jian, a second-level inspector at the Beijing Municipal Science & Technology Commission and the Zhongguancun Administrative Committee, stated at the conference, “We are confident that, with the enhanced synergy between municipal and district authorities, Beijing will”CGTThe industry is certain to achieve remarkable results.”

Cui Ying, a member of the Party Leadership Group and Deputy District Mayor of the Haidian District People’s Government in Beijing, pointed out that Haidian relies on Tsinghua University, Peking University, and other institutions within the district.37such as higher education institutions, Peking University Third Hospital, and Peking University Cancer Hospital57hospitals at Level II and above in ChinaCGTDeep accumulation in the field has created a “talent highland” where innovative R&D and clinical resources converge.Meanwhile, it has gathered BioMap, ImmunoCellular Therapeutics,Innovicon, Northland and other innovative enterprises dedicated to the research and development of cell and gene therapy drugs, forCGT...frontier areas, providing sustained momentum for innovation. Haidian will join hands with all sectors by embracing openness in policy, data, space, and mechanisms, to jointly promote China’sCGTThe industry has achieved a leap from “following” to “leading.”

Address by Cui Ying, Member of the Party Leadership Group and Deputy District Mayor of the People’s Government of Haidian District, Beijing

“As a pilot zone for institutional innovation, Haidian District is making every effort to promote”CGT“Full-chain industrial development,” introduced Yuan Xueqin, Deputy Director of the Third Division for Industrial Promotion under the Administrative Committee of Zhongguancun Science City. At the policy level, action plans and several measures have been released to anchor the direction for industrial development. In terms of spatial layout, specializedCGTIndustrial clusters provide high-quality development platforms for enterprises. In terms of services, we are cultivating a global incubation platform for the future pharmaceutical and health industries and have established the Beijing Drug and Medical Device Innovation Service Station (Haidian Station) to offer one-stop services. Furthermore, we are actively opening up medical application scenarios to promote in-depth collaboration between healthcare providers and enterprises. Notably, we are building China’s first trusted data space for pharmaceuticals and healthcare, integrating diverse data sources to inject strong momentum into industrial innovation and facilitateCGTThe Industry Reaches New Heights.

The first day of the conference yielded fruitful results.CSGCTThe China Cell and Gene Therapy Alliance Announced Its Establishment, by the United StatesASGCTone of the foundersMark A. Kayco-founded by professors, will maintain close collaboration in the future to build an international platform integrating scientific research and communication, thereby facilitating broader international cooperation and resource sharing in the field of cell and gene therapy. It released the “Blue Book on the Development of China’s Cell and Gene Therapy Industry and Interpretation of Regulatory Policies,” providingCGTIn-depth Dialogue Between Industry and Regulation Builds an Authoritative Bridge. Establishing a Global Incubation Platform for the Future of Medicine and Health, Leveraging the Zhongguancun Pre-incubation Innovation Center to Comprehensively Upgrade the Data Infrastructure, Technology Platforms, and Support Mechanisms, DrivingCGT, multi-omics and precision medicine, brain-computer interfaces,AIThe development of four core technological domains in healthcare has injected strong momentum into Beijing’s efforts to establish itself as a world-leading hub for future industries, propelling cell and gene therapy technologies to achieve leapfrog development in Haidian, a vibrant hotbed of innovation.

CSGCTEstablishment of the China Cell and Gene Therapy Alliance

At the meeting,AskBioFounderRichard Jude Samulski、ASGCTFounding MembersMark A. Kayand other international experts separately addressed the globalCGTdiscussions on topics such as opportunities and challenges, international collaboration, etc.Arbor BiotechnologiesCo-founderWinston X. YanShared the most cutting-edge advances in gene editing,HEK 293Cell Line DiscovererFrank L. GrahamReview of the History and Impact of This Cell Line.

Richard Jude SamulskiDeliver a Speech

Mark A. KayDeliver a Speech

Winston X. YanDeliver a Speech

Frank L. GrahamDelivering a Speech

In “ChinaCGT“Ecological Practices and Building Global Competitiveness” Roundtable Discussion, Director of the Hainan Boao Lecheng International Medical Tourism Pilot Zone AdministrationFu Sheng, Li Ning, Vice President of the Cancer Hospital of the Chinese Academy of Medical Sciences, and Chairman of Belief MedicineXiao Xiao, Zonghai Li, founder of CARsgen Therapeutics, and ImmuneOncoCEOHe Ting and other guests engage in in-depth dialogue to jointly chart the course for ChinaCGTNew Global Development Strategy.

"ChinaCGT“Ecological Practices and Building Global Competitiveness” Roundtable Discussion

Over the two-day conference, the assembly established15sub-forums, covering multiple cutting-edge areas such as gene therapy, immune cell therapy, stem cells and exosomes, gene editing, and tumor vaccines, and extending toCMCwith testing,AI+Drug R&D, Regulatory Registration, Investment & Financing, andBDkey links in the industrial chain, such as collaboration.

Gene Therapy Sub-forum FocusCNSdiseases, ophthalmology and otology, cardiovascular and metabolic diseases, and other fields; the cell therapy forum covers major areas such as oncology and autoimmune diseases; in addition, next-generationin vivo CAR-T、IPSCDerivative drugs, small nucleic acid drug delivery systems, and other topics have become the focus of heated discussion.

At the sub-forum titled “Frontier Innovations in Gene Therapy Across Diverse Disease Areas,” multiple industry leaders delivered speeches.Uni-Pioneers BioMed Inc.Co-founder Xiao Bin sharedAAV5Breakthroughs in the engineering of vectors for liver- and heart-targeted delivery; Xiao Xiao, Chairman of Beini Medicine, discussed the pathway for expanding gene therapy from rare diseases to common conditions; Chen Xiongwen, Dean of the School of Pharmacy at Tianjin Medical University, presented the latest advances in gene therapy for cardiac diseases. Dong Biao, Founder of Zhishan Weixin; Wu Haoquan, Founder of Kanglin Biotech; Lingyi BiotechCEOLin Qing et al. also separately addressedrAAVDrug Development, Thalassemia Treatment, Next-GenerationAAVExpress views on issues such as technology.

“In the Wave of Next-Generation Immune Cell Therapies—In Vivo Car-t“Venue, fromCapstanCo-founder ofHamideh ParhizRegardingmRNAReport on In Vivo Engineered Cell Technology. Experts including Zhang Dan, Co-founder and Chief Strategy Officer of ClinPharm; Professor Mei Heng from Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; and Yang Hanshuo, Founder of Zhenyu Biologics, discussed in vivo and ex vivoCAR-TIn-depth discussions on technical comparisons, clinical development strategies, and more. Multiple roundtable dialogues brought togetherYuanmai CellCo-founder Chen Yijun, Huanma BioCEOTang Chenxiang, Gao Lu, Chairman of Yuanin Biotech, and Fengxun BiotechCEOCorporate representatives, including Shi Kaikai, discussed technical roadmaps and prospects for industrialization.

Chief Scientist at BioMap (AILarge Models) Li Ziqing, Lai Caida, Co-founder of Metagenomi Tech; Li Linxian, Founder of DeepSure Bio; Wang Gang, Founder of Buyang Gene, and other corporate representatives, discussedAISharing insights on cutting-edge frontiers such as virtual cells, all-atom generative models, vector design, gene editor optimization, and nano-delivery.

The conference features two dedicated project pitch sessions, categorized into gene therapy, nucleic acid drugs, and gene editing, as well as immune cell therapy and stem cell therapy, establishing an efficient matchmaking channel between innovative enterprises and international capital. Prominent investment institutions, including Lilly Asia Ventures and Legend Capital, participated in the matchmaking process to help companies expand their financing channels and accelerate their global expansion.

CSGCTAs one of the most influential international conferences in the field of cell and gene therapy in China, the conference has always been committed to promoting the full-chain synergy of basic research, technological development, clinical trials, industrial translation, and global cooperation.2025The successful convening of the annual conference once again demonstrates China’s globalCGTThe field’s growing influence and innovative vitality.

In the future,CSGCTWe will continue to build an open, authoritative, and efficient global dialogue mechanism, facilitating the deep participation of China’s cell and gene therapy industry in global innovation and standard-setting, and contributing Chinese wisdom and solutions to the advancement of human health.